|
gptkbp:instanceOf
|
gptkb:antibiotic
cephalosporin
|
|
gptkbp:approvedInUS
|
1971
|
|
gptkbp:ATCCode
|
gptkb:J01DB01
|
|
gptkbp:brand
|
gptkb:Ceporex
gptkb:Rilexine
gptkb:Keflex
|
|
gptkbp:CASNumber
|
15686-71-2
|
|
gptkbp:chemicalFormula
|
beta-lactam ring
|
|
gptkbp:contraindication
|
allergy to cephalosporins
allergy to penicillins
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredIn
|
1967
|
|
gptkbp:eliminationHalfLife
|
0.5–1.2 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C16H17N3O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cephalexin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
10–15%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
|
|
gptkbp:treatment
|
skin infections
urinary tract infections
respiratory tract infections
bone infections
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:cephalosporins
|
|
gptkbp:bfsLayer
|
6
|